NIPH Clinical Trials Search

EVERIMEN Study

Basic Information

Recruitment status	Recruiting
Health condition(s) or Problem(s) studied	androgenetic alopecia
Date of first enrollment	06/06/2025
Target sample size	10
Countries of recruitment
Study type	Interventional
Intervention(s)	The investigational drug Stemsap-A will be administered via intradermal injection into the scalp dermis. This will be performed a total of 8 times at 4-week intervals.

Outcome(s)

Primary Outcome	Change in scalp hair density from baseline to 32 weeks of treatment (strands/cm2)
Secondary Outcome	1) Changes in scalp hair density (strands/cm2) 2) Modified Global Photographic Assessment (MGPA) score at 16, 32 and 52 weeks post-treatment 3) Changes in Dermatology Life Quality Index (DLQI) 4) Subject satisfaction with treatment at 32 and 52 weeks

Key inclusion & exclusion criteria

Age minimum	>= 18age old
Age maximum	Not applicable
Gender	Male
Include criteria	1) Patients diagnosed with androgenetic alopecia in males 2) Patients diagnosed with Hamilton-Norwood classification type II Vertex, III Vertex, IV, and V 3) Patients who have used minoxidil, 5-alpha reductase inhibitors, or both in the past (including ongoing use) but are dissatisfied with the results and wish to receive stem cell supernatant fluid 4) Patients aged 18 years or older 5) Patients who have given written informed consent
Exclude criteria	1) Patients undergoing treatment for malignant tumours 2) Patients with concurrent hair loss other than androgenetic alopecia 3) Patients who have previously undergone stem cell supernatant solution treatment for the scalp 4) Patients who have started or changed their treatment for androgenetic alopecia within 6 months prior to obtaining consent 5) Patients currently participating in another clinical trial 6) Patients deemed inappropriate as subjects by the principal investigator (subinvestigator)